Literature DB >> 9789213

Growth and survival of B-chronic lymphocytic leukaemia cells.

O Söderberg1.   

Abstract

Although chronic lymphocytic leukaemia of B cell type (B-CLL) is the most common form of leukaemia in the Western world, several questions about the biology of B-CLL remain to be clarified. To obtain a conceptual model for B-CLL, defined as a relentless accumulation of resting B-CLL cells, it is particularly relevant to ask which cell type is the normal counterpart of B-CLL; what is the site of proliferation; which signals are involved in the recruitment and induction of proliferation and which signals contribute to the survival of the B-CLL cells? The significance of the studies on B-CLL cells in vitro for the interpretation of the in vivo situation may be questioned since they oversimplify the multiple and complex cellular interactions that occur in vivo. However, the in vitro studies have been instrumental in elucidating signals that may regulate growth, differentiation and survival of B-CLL cells. This knowledge, herein reviewed, can be used to put forward a hypothesis on B-CLL cell regulation in vivo.

Entities:  

Mesh:

Year:  1998        PMID: 9789213     DOI: 10.1007/bf02989583

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  74 in total

Review 1.  Maturation and dispersal of B-cell clones during T cell-dependent antibody responses.

Authors:  I C MacLennan; Y J Liu; G D Johnson
Journal:  Immunol Rev       Date:  1992-04       Impact factor: 12.988

2.  CD4, CD8 and NK subsets in B-CLL.

Authors:  F Vuillier; P Tortevoye; J L Binet; G Dighiero
Journal:  Nouv Rev Fr Hematol       Date:  1988

3.  Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells.

Authors:  A C Lankester; G M van Schijndel; C E van der Schoot; M H van Oers; C J van Noesel; R A van Lier
Journal:  Blood       Date:  1995-08-01       Impact factor: 22.113

4.  Functional heterogeneity of B-CLL lymphocytes: dissociated responsiveness to growth factors and distinct requirements for a first activation signal.

Authors:  S Karray; H Merle-Béral; A Vazquez; J P Gerard; P Debre; P Galanaud
Journal:  Blood       Date:  1987-10       Impact factor: 22.113

5.  Co-stimulation by anti-immunoglobulin is required for B cell activation by CD40Llow T cells.

Authors:  J Poudrier; T Owens
Journal:  Eur J Immunol       Date:  1994-12       Impact factor: 5.532

6.  Serum levels of helper factors (IL-1 alpha, IL-1 beta and IL-6), T-cell products (sCD4 and sCD8), sIL-2R and beta 2-microglobulin in patients with B-CLL and benign B lymphocytosis.

Authors:  M Aguilar-Santelises; A Loftenius; C Ljungh; S B Svenson; B Andersson; H Mellstedt; M Jondal
Journal:  Leuk Res       Date:  1992 Jun-Jul       Impact factor: 3.156

7.  Characterization of interleukin 2 receptors on B-cell chronic lymphocytic leukemia cells.

Authors:  V Tsilivakos; A Tsapis; S Kakolyris; P Iliakis; M Perraki; V Georgoulias
Journal:  Leukemia       Date:  1994-09       Impact factor: 11.528

8.  Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors.

Authors:  A C Fluckiger; J F Rossi; A Bussel; P Bryon; J Banchereau; T Defrance
Journal:  Blood       Date:  1992-12-15       Impact factor: 22.113

Review 9.  Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system?

Authors:  J Burton; N E Kay
Journal:  Leukemia       Date:  1994-01       Impact factor: 11.528

10.  Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: correlation with disease status and neoplastic phenotype.

Authors:  U Dianzani; P Omedè; F Marmont; D DiFranco; A Fusaro; M Bragardo; V Redoglia; F Giaretta; L Mairone; M Boccadoro
Journal:  Blood       Date:  1994-04-15       Impact factor: 22.113

View more
  1 in total

1.  Cytokine expression in B-CLL in relation to disease progression and in vitro activation.

Authors:  M Aguilar-Santelises; D Gigliotti; L M Osorio; A D Santiago; H Mellstedt; M Jondal
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.